Pediatrics in Review Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 28 No. 7, July 2007
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Driscoll, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Driscoll, M. C.

(Pediatrics in Review. 2007;28:259-268.)
© 2007 American Academy of Pediatrics

Sickle Cell Disease


M. Catherine Driscoll, MD*
 * Director, Hematology Program, Children's Hospital at Montefiore, Bronx, NY

The first 300 words of the full text of this article appear below.


   Objectives
 
After completing this article, readers should be able to:

  1. Describe the pathogenesis of sickle cell disease.
  2. Delineate the complications of sickle cell disease and their management.
  3. Review guidelines for health maintenance and preventive measures.
  4. Discuss the current treatments for sickle cell disease.


   Introduction
 
Sickle cell disease (SCD) is a chronic hemolytic anemia that includes the hemoglobin (Hb) variants SS, SC, S-beta thalassemia, SO Arab, SD, and other rare S-Hb genotypes. SCD is one of the most common genetic diseases worldwide. Sickle disorders are seen commonly in sub-Saharan Africa but also occur in the Mediterranean, India, and the Arabian Peninsula. The geographic distribution of sickle hemoglobinopathies corresponds to the distribution of malaria; indeed, the sickle gene in the heterozygote (AS) form protects against death from endemic Plasmodium falciparum malaria infection. In addition, the clinical manifestations of SCD vary among these geographic sites, with individuals from India, the Arabian Peninsula, and Senegal having milder disease than those from parts of Africa. This pattern suggests that genetic modifiers ameliorate the disease in certain populations and contribute to the significant variation in clinical manifestations. The presence of SCD in North, South, and Central America is due to immigration patterns and represents primarily the more severe African types.


   Pathogenesis
 
The genetic defect producing sickle Hb is a single nucleotide substitution (GTG for GAG) at codon 6 of the beta globin gene on chromosome 11 that results in the substitution of valine for glutamic acid. This hydrophobic amino acid substitution allows Hb S to polymerize on deoxygenation, and multiple polymers bundle to form rodlike structures that distort the red cell into the classic crescent shape. Sickled red cells are less deformable in the microcirculation and provoke a cascade of events that results in vascular occlusion, organ ischemia, and eventually, chronic end-organ damage. The ancillary events of polymerization that . . . [Full Text of this Article]






HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Pediatrics Pediatrics in Review
Copyright © 2007 by the American Academy of Pediatrics.